Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
6 pending office actions • 2 clients • 6 examiners • 6 art units • 0 of 6 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Meunier Carlin & Curfman LLC & Poly-Med has 80 career applications in Biotechnology & Pharmaceuticals and 7 pending office actions. The resolved allowance rate is 84.78%, indicating that most resolved applications reached allowance.
The average of 7.44 office actions per allowance is notably high within this profile, showing that allowed cases typically required extended examination activity. Practitioners may view this as evidence that prosecution in this matter set involved substantial persistence and claim development.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| Double-patenting only | 1 (17%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BYRD, BRIGID K | 1 | 71.4% | +46.4% |
| CAI, WENWEN | 1 | 59.9% | +19.4% |
| WORRELL, KEVIN | 1 | 12.5% | -3.1% |
| GALSTER, SAMUEL LEONARD | 1 | 52.1% | +42.2% |
| BAKSHI, PANCHAM | 1 | 76.7% | +30.2% |
| GHALI, ISIS A D | 1 | 27.9% | +41.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17636339 | COMPOSITIONS FOR SUNSCREEN COMPOUNDS AND METHODS THEREOF | BAKSHI, PANCHAM | 79d overdue |
| 15301281 | CONTRACEPTIVE AND RELATED DEVICE | GHALI, ISIS A D | 26d |
| 18604036 | POLYMERIC MESH PRODUCTS, METHOD OF MAKING AND USE THEREOF | WORRELL, KEVIN | 70d |
| 18937342 | POLYMERS FOR ADDITIVE MANUFACTURING | CAI, WENWEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17636339 | COMPOSITIONS FOR SUNSCREEN COMPOUNDS AND METHODS THEREOF | BAKSHI, PANCHAM | 79d overdue |
| 15301281 | CONTRACEPTIVE AND RELATED DEVICE | GHALI, ISIS A D | 26d |
| 18265111 | FUNCTIONALIZED AND CROSSLINKED POLYMERS | GALSTER, SAMUEL LEONARD | 75d |
| 19197122 | TIME DEPENDENT PHYSIOLOGIC TISSUE SCAFFOLD | BYRD, BRIGID K | — |
| 18937342 | POLYMERS FOR ADDITIVE MANUFACTURING | CAI, WENWEN | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Poly-Med | 4 |
| PMIDG, LLC | 2 |
| Art Unit | Apps |
|---|---|
| 3771 | 1 |
| 1743 | 1 |
| 1789 | 1 |
| 1693 | 1 |
| 1623 | 1 |
| 1611 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19197122 | TIME DEPENDENT PHYSIOLOGIC TISSUE SCAFFOLD | Poly-Med, Inc. | BYRD, BRIGID K | 3771 | §102§103§112DP | Non-Final OA | — | Pending | May 02, 2025 |
| 18937342 | POLYMERS FOR ADDITIVE MANUFACTURING | Poly-Med, Inc. | CAI, WENWEN | 1743 | §102§103§112 | Non-Final OA | — | Pending | Nov 05, 2024 |
| 18604036 | POLYMERIC MESH PRODUCTS, METHOD OF MAKING AND USE THEREOF | Poly-Med, Inc. | WORRELL, KEVIN | 1789 | DP | Non-Final OA | 70d | Pending | Mar 13, 2024 |
| 18265111 | FUNCTIONALIZED AND CROSSLINKED POLYMERS | Pmidg, LLC | GALSTER, SAMUEL LEONARD | 1693 | §102§103§112DP | Non-Final OA | 75d | Pending | Jun 02, 2023 |
| 17636339 | COMPOSITIONS FOR SUNSCREEN COMPOUNDS AND METHODS THEREOF | Pmidg, LLC | BAKSHI, PANCHAM | 1623 | §102§112 | Final Rejection | 79d overdue | Pending | Feb 17, 2022 |
| 15301281 | CONTRACEPTIVE AND RELATED DEVICE | Poly-Med, Inc. | GHALI, ISIS A D | 1611 | §103 | Final Rejection | 26d | Pending | Sep 30, 2016 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial84.8% of resolved applications prosecuted by Meunier Carlin & Curfman LLC & Poly-Med were allowed, across 80 applications in USPTO records.
7.44 office actions per allowed application on average.
6 pending office actions as of October 2026, for 2 clients, before 6 examiners in 6 art units.
